# Efficacy and Safety of MP-424, Peginterferon Alfa-2b, and Ribavirin in Patients With Chronic Hepatitis C Who Relapsed After Previous Interferon Based Therapy

> **NCT00780910** · PHASE3 · COMPLETED · sponsor: **Tanabe Pharma Corporation** · enrollment: 109 (actual)

## Conditions studied

- Chronic Hepatitis C

## Interventions

- **DRUG:** MP-424
- **DRUG:** Ribavirin
- **DRUG:** Peginterferon Alfa-2b

## Key facts

- **NCT ID:** NCT00780910
- **Lead sponsor:** Tanabe Pharma Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-11
- **Primary completion:** 2010-10
- **Final completion:** 2010-10
- **Target enrollment:** 109 (ACTUAL)
- **Last updated:** 2026-01-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00780910

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00780910, "Efficacy and Safety of MP-424, Peginterferon Alfa-2b, and Ribavirin in Patients With Chronic Hepatitis C Who Relapsed After Previous Interferon Based Therapy". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT00780910. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*